These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23722626)

  • 21. Multi-target drugs: the trend of drug research and development.
    Lu JJ; Pan W; Hu YJ; Wang YT
    PLoS One; 2012; 7(6):e40262. PubMed ID: 22768266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new prize system for drug innovation.
    Gandjour A; Chernyak N
    Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
    Puente J; Gascon F; Ponte B; de la Fuente D
    Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical Drug Innovation From 2000 Through 2014.
    Walter JR; Xu S
    JAMA Dermatol; 2015 Jul; 151(7):792-4. PubMed ID: 25807060
    [No Abstract]   [Full Text] [Related]  

  • 26. The importance of new companies for drug discovery: origins of a decade of new drugs.
    Kneller R
    Nat Rev Drug Discov; 2010 Nov; 9(11):867-82. PubMed ID: 21031002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic innovation for future public health needs.
    Theuretzbacher U
    Clin Microbiol Infect; 2017 Oct; 23(10):713-717. PubMed ID: 28652114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
    Turner MJ
    Drug Discov Today; 2015 Aug; 20(8):917-9. PubMed ID: 26100736
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 33. The rise (and decline?) of biotechnology.
    Kinch MS
    Drug Discov Today; 2014 Nov; 19(11):1686-1690. PubMed ID: 24747562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 35. There is no better time than the present: nanotechnology as a disruptive innovation for drug development.
    Oo C; Tsai JC; Kao HD
    Drug Discov Today; 2015 Jun; 20(6):645-7. PubMed ID: 25835226
    [No Abstract]   [Full Text] [Related]  

  • 36. Measuring the effectiveness and impact of an open innovation platform.
    Carroll GP; Srivastava S; Volini AS; Piñeiro-Núñez MM; Vetman T
    Drug Discov Today; 2017 May; 22(5):776-785. PubMed ID: 28137644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R; McGrath C; Herings R
    Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can expedited FDA drug approval without expedited follow-up be trusted?
    Carpenter D
    JAMA Intern Med; 2014 Jan; 174(1):95-7. PubMed ID: 24165977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.